Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Paediatric rhabdomyosarcoma survival extended with maintenance chemotherapy

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.18
Views: 525

Dr Gianni Bisogno - University Hospital of Padova, Padova, Italy

Dr Bisogno presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from a randomised phase III clinical trial of 6 months maintenance chemotherapy for children with the rare disease rhabdomyosarcoma.

For those receiving the low dose chemotherapy following initial treatments, 5 year overall survival improved from 73.7% to 86.5%, which is the first improvement in this indication for more than 30 years.

For more detail, watch Dr Bisogno speak with ecancer about the trial here, or read our news coverage here.

Slides from this presentation are available here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation